A-375 - Cell Line (ID:50060)

HMS LINCS ID: 50060
Name: A-375
Alternative Names: A375
LINCS ID: LCL-1235
Alternative ID: CLO_0001582
Parent Cell Line:
Reference Source: ATCC CRL-1619
Organism: Homo sapiens
Organ: skin
Tissue:
Cell Type: epithelial
Details of Cell Type:
Donor Sex: female
Donor Age:
Donor Ethnicity:
Donor Health Status:
Disease: DOID:1909, malignant melanoma
Details of Disease:
Production Details:
Genetic Modification(s): none
Known Mutations:
Citation Information for Mutations: COSS906793
Verification Reference Profile: DNA Profile (STR, source: ATCC): Amelogenin: X CSF1PO: 11,12 D13S317: 11,14 D16S539: 9 D5S818: 12 D7S820: 9 THO1: 8 TPOX: 8,10 vWA: 16,17
Growth Properties: adherent
Recommended Culture Conditions: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0 deg C Subculturing protocol: Remove and discard culture medium. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37 deg C to facilitate dispersal. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting. Add appropriate aliquots of the cell suspension to new culture vessels. Incubate cultures at 37 deg C. Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended Medium Renewal: Every 2 to 3 days
Relevant Citations:
Usage Note:
Comments:
Date Publicly Available: 2012-05-01
Most Recent Update: 2016-07-12

Datasets:

HMS Dataset ID Dataset Title HMS Dataset Type
20087
Sorafenib KiNativ -- dose response experiment
KiNativ
20088
GW-5074 KiNativ -- dose response experiment
KiNativ
20089
SB590885 KiNativ -- dose response experiment
KiNativ
20090
PLX-4720 KiNativ -- dose response experiment
KiNativ
20091
AZ-628 KiNativ -- dose response experiment
KiNativ
20092
PLX4032 KiNativ -- dose response experiment
KiNativ
20093
HG-6-64-01 KiNativ -- single dose experiment
KiNativ
20213
JNK-IN-8 KiNativ -- single dose experiment
KiNativ
20272
Viability and apoptosis measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (viability/apoptosis dataset 1 of 2)
Microscopy/Imaging
20273
Viability and apoptosis measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of three compounds (viability/apoptosis dataset 2 of 2)
Microscopy/Imaging
20274
Phosphorylation state and protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (immunofluorescence dataset 1 of 4)
Microscopy/Imaging
20275
Phosphorylation state and protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (immunofluorescence dataset 2 of 4)
Microscopy/Imaging
20276
Protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with Vemurafenib in combination with chromatin-targeting compounds (immunofluorescence dataset 3 of 4)
Microscopy/Imaging
20277
Phosphorylation state and protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (immunofluorescence dataset 4 of 4)
Microscopy/Imaging

Batch Information:

HMS LINCS Batch ID Provider Provider Catalog ID Provider Batch ID
50060-1 ActivX Biosciences, Inc.
50060-2 Nienke Moret (Harvard Medical School)